Pretargeted radioimmunotherapy (PRIT) in progressive medullary thyroid cancer (MTC) using bispecific antibody and iodine 131-labeled bivalent hapten:: Preliminary results of a phase II clinical trial

被引：0
|
作者：
Salaun, P-Y [1 ,7 ]
Bournaud, C. [2 ]
Oudoux, A. [1 ]
Bardet, S. [3 ]
Vuillez, J-P [4 ]
Taieb, D. [5 ]
Ansquer, C. [1 ]
Rousseau, C. [6 ]
Bridji, B. [6 ]
Borson-Chazot, F. [2 ]
Barbet, J. [7 ]
Goldenberg, D. M. [8 ]
Chatal, J-F [7 ]
Kraeber-Bodere, F. [1 ,6 ,7 ]
机构：
[1] Univ Hosp Nantes, Dept Nucl Med, Nantes, France
[2] Univ Hosp Lyon, Dept Nucl Med, Lyon, France
[3] Baclesse Canc Inst, Dept Nucl Med, Caen, France
[4] Univ Hosp Grenoble, Dept Nucl Med, Grenoble, France
[5] Univ Hosp Marseille, Dept Nucl Med, Marseille, France
[6] Gauducheau Canc Inst, Dept Nucl Med, Nantes, France
[7] INSERM, U 896, Nantes, France
[8] Ctr Mol Med & Immunol, Belleville, NJ USA
来源：
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 2008年 / 23卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
33
引用
收藏
页码：524 / 524
页数：1
相关论文
共 23 条
  • [1] Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten:: Preliminary results of a phase I/II clinical trial
    Kraeber-Bodéré, F
    Bardet, S
    Hoefnagel, CA
    Vieira, MR
    Vuillez, JP
    Murat, A
    Ferreira, TC
    Bardiès, M
    Ferrer, L
    Resche, I
    Gautherot, E
    Rouvier, E
    Barbet, J
    Chatal, JF
    CLINICAL CANCER RESEARCH, 1999, 5 (10) : 3190S - 3198S
  • [2] Phase I/II trial of two step radioimmunotherapy in medullary thyroid cancer (MTC) using bispecific anti-CEA/anti-DTPA-In antibody and iodine-131-labeled bivalent hapten.
    Bodere, FK
    Bardet, S
    Vuillez, JP
    Bardies, M
    Gautherot, E
    Rouvier, E
    Barbet, J
    Chatal, JF
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 246P - 246P
  • [3] Radioimmunotherapy (RIT) with bispecific antibody and I-131-labeled bivalent hapten in nude mice bearing a human medullary thyroid carcinoma (MTC).
    KraeberBodere, F
    FaivreChauvet, A
    SaiMaurel, C
    LeBoterff, J
    Gautherot, E
    Barbet, J
    Chatal, JF
    Thedrez, P
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 105 - 105
  • [4] Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft:: Comparison of iodine 131-labeled F(ab′)2 and pretargeted bivalent hapten and evaluation of repeated injections
    Kraeber-Bodéré, F
    Faivre-Chauvet, A
    Saï-Maurel, C
    Campion, L
    Fiche, M
    Gautherot, E
    Le Boterff, J
    Barbet, J
    Chatal, JF
    Thédrez, P
    CLINICAL CANCER RESEARCH, 1999, 5 (10) : 3183S - 3189S
  • [5] Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer
    Bardies, M
    Bardet, S
    FaivreChauvet, A
    Peltier, P
    Douillard, JY
    Mahe, M
    Fiche, M
    Lisbona, A
    Giacalone, F
    Meyer, P
    Gautherot, E
    Rouvier, E
    Barbet, J
    Chatal, JF
    JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (11) : 1853 - 1859
  • [6] Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial
    Kraeber-Bodéré, F
    Rousseau, C
    Bodet-Milin, C
    Ferrer, L
    Faivre-Chauvet, A
    Campion, L
    Vuillez, JP
    Devillers, A
    Chang, CH
    Goldenberg, DM
    Chatal, JF
    Barbet, J
    JOURNAL OF NUCLEAR MEDICINE, 2006, 47 (02) : 247 - 255
  • [7] Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten
    Hosono, M
    Hosono, MN
    Kraeber-Bodéré, F
    Devys, A
    Thédrez, P
    Fiche, M
    Gautherot, E
    Barbet, J
    Chatal, JF
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (09) : 1608 - 1613
  • [8] Results of a pretargeted radioimmunotherapy (RIT) phase I/II trial in medullary thyroid carcinoma (MTC): Biological markers and effects on survival
    Barbet, J
    Kraeber-Bodere, F
    Campion, L
    Chatal, JF
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2004, 19 (04) : 523 - 523
  • [9] Clinical studies of pretargeted, two-step radioimmunotherapy (RAIT) with bispecific antibody (BsMAb) and 131I-labeled bivalent hapten in patients with CEA-expressing cancers.
    Chatal, J
    Kraeber-Bodere, F
    Faivre-Chauvet, A
    Cerato, E
    Devellers, A
    Sharkey, RM
    Chang, K
    Barbet, J
    Goldenberg, DM
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3787S - 3787S
  • [10] Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of iodine-131-labeled hapten in a phase I radioimmunotherapy trial
    Kraeber-Bodéré, F
    Faivre-Chauvet, A
    Ferrer, L
    Vuillez, JP
    Brard, PY
    Rousseau, C
    Resche, I
    Devillers, A
    Laffont, S
    Bardiès, M
    Chang, K
    Sharkey, RM
    Goldenberg, DM
    Chatal, JF
    Barbet, J
    CLINICAL CANCER RESEARCH, 2003, 9 (10) : 3973S - 3981S
123